<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of kidney disease associated with hepatitis C virus infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of kidney disease associated with hepatitis C virus infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of kidney disease associated with hepatitis C virus infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nassim Kamar, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lionel Rostaing, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There is a strong and likely causal association between chronic hepatitis C virus (HCV) infection and glomerular disease [<a href="#rid1">1-5</a>]. Several types of kidney disease have been recognized including mixed cryoglobulinemia, membranoproliferative glomerulonephritis (MPGN), membranous nephropathy [<a href="#rid6">6-12</a>], and polyarteritis nodosa (PAN). Crescentic glomerulonephritis may be superimposed on any of these glomerular lesions.</p><p>Less commonly, other glomerular lesions have been reported in HCV-infected patients, including focal segmental glomerulosclerosis (FSGS) [<a href="#rid13">13-15</a>], proliferative glomerulonephritis [<a href="#rid16">16-18</a>], and fibrillary [<a href="#rid19">19-21</a>] and immunotactoid glomerulopathies [<a href="#rid20">20</a>]. In some patients, glomerular disease may be clinically silent [<a href="#rid22">22,23</a>]. (See <a class="local">'Types of glomerular disease associated with hepatitis C infection'</a> below.)</p><p>Glomerular diseases associated with HCV can also occur in kidney allografts. These issues are presented in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p>This topic provides an overview of the kidney diseases associated with chronic HCV infection. The diagnosis of HCV infection, treatment of HCV infection in patients with kidney disease, and evaluation and management of HCV-associated kidney disease following kidney transplantation are discussed in other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p></p><p class="headingAnchor" id="H553386463"><span class="h1">TYPES OF GLOMERULAR DISEASE ASSOCIATED WITH HEPATITIS C INFECTION</span><span class="headingEndMark"> — </span>The major glomerular diseases associated with HCV infection include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed cryoglobulinemia syndrome (see <a class="local">'Mixed cryoglobulinemia syndrome'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Membranous nephropathy (see <a class="local">'Membranous nephropathy'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyarteritis nodosa (PAN) (see <a class="local">'Polyarteritis nodosa'</a> below)</p><p></p><p>In addition to symptomatic kidney disease, clinically silent glomerular disease has been described in patients with HCV infection, primarily in those who have undergone liver transplantation for cirrhosis due to chronic HCV infection [<a href="#rid22">22,23</a>]. In a series of 48 such patients, 30 had a kidney biopsy during surgery; the remaining patients either did not consent or were considered at risk for complications from kidney biopsy [<a href="#rid22">22</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune complex glomerulonephritis was present in 25, which was classified as membranoproliferative glomerulonephritis (MPGN) in 12, immunoglobulin A (IgA) nephropathy in 7, and mesangial glomerulonephritis in 6 patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical kidney abnormality (elevated serum creatinine, hematuria, and/or proteinuria) was noted in only 10 patients, most of whom had MPGN.</p><p></p><p>Posttransplant follow-up was not reported. Thus, the impact of clinically silent glomerular disease at the time of transplant upon kidney and other outcomes following liver transplantation is unknown. (See  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H553386529"><span class="h2">Mixed cryoglobulinemia syndrome</span><span class="headingEndMark"> — </span>Mixed cryoglobulinemia syndrome is a systemic vasculitis. Affected patients typically present with nonspecific systemic symptoms, palpable purpura, arthralgias, fever, kidney disease, neuropathy, and other manifestations [<a href="#rid24">24</a>]. The clinical manifestations of the kidney disease may include hematuria, proteinuria (which may be in the nephrotic range), and kidney function impairment. A detailed discussion of the kidney manifestations, including histologic findings, in patients with mixed cryoglobulinemia syndrome is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Kidney involvement'</a>.)</p><p>Laboratory studies indicate the presence of hypocomplementemia and circulating cryoglobulins. The complement components, C3, C4, and C1q, are usually low; reductions in C4 are usually greater than reductions in C3. Cryoglobulins are most commonly type II, characterized by a polyclonal immunoglobulin G (IgG) and monoclonal immunoglobulin M (IgM) kappa rheumatoid factor directed against the Fc portion of IgG. (See  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Most patients with mixed cryoglobulinemia syndrome have HCV infection, and there is strong evidence that HCV-containing immune complexes are directly involved in the pathogenesis of disease. HCV RNA and HCV IgG antigen-antibody complexes are highly concentrated in the cryoprecipitate. In addition, HCV antigens have been detected along the glomerular capillary walls and in the mesangium of patients with HCV-related glomerulonephritis, mainly in those with MPGN and positive HCV RNA. (See  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Tissue biopsy in selected patients'</a> and  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Infections'</a>.)</p><p>Although HCV infection is primarily associated with type II mixed cryoglobulinemia, it may also be responsible for some cases of type III mixed cryoglobulinemia. Type III cryoglobulinemia is characterized by circulating cryoglobulins comprised of polyclonal IgG and polyclonal IgM. (See  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Terminology'</a>.)</p><p>Histologic examination of kidney biopsies demonstrates glomerular infiltration by activated macrophages. The glomerular basement membrane shows double contours caused by the interposition of monocytes between the basement membrane and the endothelium. Subendothelial deposits of IgM, IgG, and complement components are observed by immunofluorescence and electron microscopy. Vasculitis of small renal arteries is sometimes present. (See  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Tissue biopsy in selected patients'</a>.)</p><p class="headingAnchor" id="H3"><span class="h3">Membranoproliferative glomerulonephritis without cryoglobulins</span><span class="headingEndMark"> — </span>The association of HCV infection with immune complex-mediated MPGN in the <strong>absence</strong> of cryoglobulinemia is controversial. Although such patients have been described [<a href="#rid13">13,25-27</a>], most of these patients subsequently developed measurable cryoglobulins, although not necessarily in conjunction with extrarenal manifestations of cryoglobulinemia [<a href="#rid6">6,10,18</a>]. Circulating cryoglobulins are often difficult to detect, and cryoglobulinemia may be unrecognized in many patients. (See  <a class="medical medical_review" href="/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Membranous nephropathy</span><span class="headingEndMark"> — </span>It is not clear whether there is an association between membranous nephropathy and HCV infection. Several small studies have suggested that membranous nephropathy may be induced by chronic HCV infection, although the data are conflicting [<a href="#rid6">6,10,13,26,28,29</a>]. In one study, the prevalence of membranous nephropathy was significantly higher in HCV-positive compared with HCV-negative kidney transplant patients [<a href="#rid30">30</a>]. However, in another study of 19 patients with membranous nephropathy, only 1 (5 percent) had anti-HCV antibodies, which was not different than that observed in control patients with diabetic nephropathy [<a href="#rid13">13</a>].</p><p>Overall, these findings suggest but do not prove a possible role of HCV in the development of membranous nephropathy. However, in contrast to the findings in mixed cryoglobulinemia syndrome or MPGN, complement levels tend to be normal, and neither cryoglobulins nor rheumatoid factor is present in HCV-associated membranous nephropathy [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Polyarteritis nodosa</span><span class="headingEndMark"> — </span>PAN is well described in patients with hepatitis B virus infection, but it also occurs in association with HCV in the absence of cryoglobulins [<a href="#rid31">31-34</a>]. In one series, among 161 patients with HCV-related vasculitis, 31 (19 percent) were diagnosed with PAN [<a href="#rid34">34</a>]. This disorder is called secondary PAN.</p><p>In a review of 78 cases, the onset of PAN occurred at a mean of two years after the diagnosis of HCV infection [<a href="#rid32">32</a>]. The patients had typical symptoms of PAN and necrotizing inflammation of medium or small arteries in biopsy specimens. Twenty-six percent of tested patients were also positive for hepatitis B surface antigen. (See  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and  <a class="medical medical_review" href="/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection", section on 'Polyarteritis nodosa (PAN)'</a>.)</p><p>Patients infected with HCV who develop PAN may have more severe systemic manifestations of vasculitis compared with those HCV patients who develop mixed cryoglobulinemia vasculitis. In the study cited above, compared with patients with HCV-related mixed cryoglobulinemia syndrome, patients with HCV-related PAN more commonly had fever, weight loss, hypertension, gastrointestinal tract involvement, severe mononeuropathy, and elevated C-reactive protein levels [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The association of HCV infection with the glomerular diseases discussed above suggests that all patients with mixed cryoglobulinemia syndrome, immune complex-mediated membranoproliferative glomerulonephritis (MPGN), membranous nephropathy, and polyarteritis nodosa (PAN) should be evaluated for possible underlying HCV infection. (See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p>In addition, HCV-infected patients should be evaluated for proteinuria, hematuria, hypertension, and a reduced glomerular filtration rate (GFR). Patients who are found to have kidney abnormalities should undergo testing for cryoglobulins, hypocomplementemia, and a positive rheumatoid factor. A kidney biopsy should be considered in the setting of significant proteinuria and/or impaired kidney function.</p><p class="headingAnchor" id="H710308139"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Patients with kidney disease infected by HCV should be offered antiviral therapy. (See  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment", section on 'Patient selection for treatment'</a>.)</p><p>In general, patients with severe and progressive HCV-associated glomerulonephritis should undergo antiviral treatment. Most patients with less severe glomerular disease associated with HCV should also have antiviral therapy provided they do not have decompensated cirrhosis. (See  <a class="medical medical_review" href="/d/html/3070.html" rel="external">"Mixed cryoglobulinemia syndrome: Treatment and prognosis", section on 'Hepatitis C infection'</a>.)</p><p>In patients who are selected for antiviral therapy, the specific regimen depends upon the estimated glomerular filtration rate (eGFR). These issues are discussed elsewhere in detail. (See  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment", section on 'Regimen selection and dosing'</a>.)</p><p>In addition to antiviral therapy, patients with severe and progressive mixed cryoglobulinemia and polyarteritis nodosa (PAN) are frequently treated with immunosuppressive drugs. Specific immunosuppressive regimens and the timing of antiviral therapy in such patients are presented separately. (See  <a class="medical medical_review" href="/d/html/3070.html" rel="external">"Mixed cryoglobulinemia syndrome: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/8244.html" rel="external">"Treatment and prognosis of polyarteritis nodosa"</a>.)</p><p class="headingAnchor" id="H209308988"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of glomerular disease associated with hepatitis C virus </strong>– There is a strong and likely causal association between chronic hepatitis C virus (HCV) infection and glomerular disease. The major glomerular diseases associated with HCV infection include the following (see <a class="local">'Types of glomerular disease associated with hepatitis C infection'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mixed cryoglobulinemia syndrome (see <a class="local">'Mixed cryoglobulinemia syndrome'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Membranous nephropathy (see <a class="local">'Membranous nephropathy'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyarteritis nodosa (PAN) (see <a class="local">'Polyarteritis nodosa'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– All patients with mixed cryoglobulinemia syndrome, immune complex-mediated membranoproliferative glomerulonephritis (MPGN), membranous nephropathy, and PAN should be evaluated for possible underlying HCV infection. In addition, HCV-infected patients should be evaluated for proteinuria, hematuria, hypertension, and a reduced glomerular filtration rate (GFR). Patients who are found to have kidney abnormalities should undergo testing for cryoglobulins, hypocomplementemia, and a positive rheumatoid factor. A kidney biopsy should be considered in the setting of significant proteinuria and/or impaired kidney function. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– In general, patients with severe and progressive HCV-associated glomerulonephritis should undergo antiviral treatment. Most patients with less severe glomerular disease associated with HCV should also have antiviral therapy provided they do not have decompensated cirrhosis. In patients who are selected for antiviral therapy, the specific regimen depends upon the estimated GFR (eGFR). These issues are discussed elsewhere in detail. (See  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Morales JM, Kamar N, Rostaing L. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol 2012; 176:10.</a></li><li><a class="nounderline abstract_t">Sabry AA, Sobh MA, Irving WL, et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17:239.</a></li><li><a class="nounderline abstract_t">Sumida K, Ubara Y, Hoshino J, et al. Hepatitis C virus-related kidney disease: various histological patterns. Clin Nephrol 2010; 74:446.</a></li><li><a class="nounderline abstract_t">Castillo I, Martinez-Ara J, Olea T, et al. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 2014; 86:619.</a></li><li><a class="nounderline abstract_t">Kupin WL. Viral-Associated GN: Hepatitis C and HIV. Clin J Am Soc Nephrol 2017; 12:1337.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46:1255.</a></li><li><a class="nounderline abstract_t">Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.</a></li><li><a class="nounderline abstract_t">Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.</a></li><li><a class="nounderline abstract_t">Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 1997; 25:1237.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.</a></li><li><a class="nounderline abstract_t">Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999; 106:347.</a></li><li><a class="nounderline abstract_t">Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002; 81:398.</a></li><li><a class="nounderline abstract_t">Cosio FG, Roche Z, Agarwal A, et al. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996; 28:752.</a></li><li><a class="nounderline abstract_t">Altraif IH, Abdulla AS, al Sebayel MI, et al. Hepatitis C associated glomerulonephritis. Am J Nephrol 1995; 15:407.</a></li><li><a class="nounderline abstract_t">Stehman-Breen C, Alpers CE, Fleet WP, Johnson RJ. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 1999; 81:37.</a></li><li><a class="nounderline abstract_t">Morales JM, Morales E, Andrès A, et al. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens 1999; 8:205.</a></li><li><a class="nounderline abstract_t">Horikoshi S, Okada T, Shirato I, et al. Diffuse proliferative glomerulonephritis with hepatitis C virus-like particles in paramesangial dense deposits in a patient with chronic hepatitis C virus hepatitis. Nephron 1993; 64:462.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46:1700.</a></li><li><a class="nounderline abstract_t">Coroneos E, Truong L, Olivero J. Fibrillary glomerulonephritis associated with hepatitis C viral infection. Am J Kidney Dis 1997; 29:132.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9:2244.</a></li><li><a class="nounderline abstract_t">Radhakrishnan J, Uppot RN, Colvin RB. Case records of the Massachusetts General Hospital. Case 5-2010. A 51-year-old man with HIV infection, proteinuria, and edema. N Engl J Med 2010; 362:636.</a></li><li><a class="nounderline abstract_t">McGuire BM, Julian BA, Bynon JS Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.</a></li><li><a class="nounderline abstract_t">Arase Y, Ikeda K, Murashima N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med 1998; 37:836.</a></li><li><a class="nounderline abstract_t">Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009; 4:207.</a></li><li><a class="nounderline abstract_t">Rostoker G, Deforges L, Ben Maadi A, et al. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. Nephron 1995; 69:97.</a></li><li><a class="nounderline abstract_t">Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6:220.</a></li><li><a class="nounderline abstract_t">Madala ND, Naicker S, Singh B, et al. The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. Clin Nephrol 2003; 60:69.</a></li><li><a class="nounderline abstract_t">Stehman-Breen C, Alpers CE, Couser WG, et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995; 44:141.</a></li><li><a class="nounderline abstract_t">Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al. Membranous glomerulonephritis associated with hepatitis C virus infection: case report and literature review. Clin Nephrol 2004; 61:144.</a></li><li><a class="nounderline abstract_t">Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63:1634.</a></li><li><a class="nounderline abstract_t">Cacoub P, Lunel-Fabiani F, Du LT. Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med 1992; 116:605.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Muñoz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36:1442.</a></li><li><a class="nounderline abstract_t">Beuthien W, Mellinghoff HU, Kempis Jv. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005; 24:507.</a></li><li><a class="nounderline abstract_t">Saadoun D, Terrier B, Semoun O, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken) 2011; 63:427.</a></li></ol></div><div id="topicVersionRevision">Topic 3065 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22310777" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812873" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A comprehensive study of the association between hepatitis C virus and glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21084048" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hepatitis C virus-related kidney disease: various histological patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646855" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27797895" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Viral-Associated GN: Hepatitis C and HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7853784" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Renal manifestations of hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1326246" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1383822" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A role for hepatitis C virus infection in type II cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141444" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7678440" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190385" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Renal manifestations of hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352634" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The clinical and morphologic spectrum of renal cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9158216" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503140" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatitis C associated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9884417" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Focal segmental glomerular sclerosis among patients infected with hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Glomerulonephritis associated with hepatitis C virus infection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8393534" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diffuse proliferative glomerulonephritis with hepatitis C virus-like particles in paramesangial dense deposits in a patient with chronic hepatitis C virus hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7535369" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9002542" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fibrillary glomerulonephritis associated with hepatitis C viral infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848778" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164488" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Case records of the Massachusetts General Hospital. Case 5-2010. A 51-year-old man with HIV infection, proteinuria, and edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702589" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840704" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Glomerulonephritis in autopsy cases with hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129320" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hepatitis C infection and chronic renal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7534382" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579088" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940606" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8556829" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hepatitis C virus associated membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14989635" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Membranous glomerulonephritis associated with hepatitis C virus infection: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9197359" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347444" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Polyarteritis nodosa and hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369460" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15988558" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20981809" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hepatitis C virus-associated polyarteritis nodosa.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
